<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Kidney transplantation in adults: Induction immunosuppressive therapy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Kidney transplantation in adults: Induction immunosuppressive therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Kidney transplantation in adults: Induction immunosuppressive therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Vella, MD, FACP, FRCP, FASN, FAST</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christophe Legendre, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 04, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3055879417"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Induction therapy is immunosuppressive therapy administered at the time of kidney transplantation to reduce the risk of allograft rejection. In general, induction strategies fall into one of two categories. The first relies upon high doses of conventional immunosuppressive agents, while the more commonly used strategy utilizes either T cell-depleting or interleukin (IL) 2 receptor-blocking antibodies in combination with lower doses of conventional agents.</p><p>This topic will review the approach to induction therapy in adults undergoing kidney transplantation. Maintenance immunosuppressive therapy for adult kidney transplant recipients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy"</a>.)</p><p class="headingAnchor" id="H3747664674"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H3193255786"><span class="h2">Indications for induction therapy</span><span class="headingEndMark"> — </span>Practically all kidney allograft recipients require immunosuppressive therapy to prevent rejection and loss of the allograft. For <strong>most</strong> patients undergoing kidney transplantation, we suggest induction therapy consisting of antibody therapy plus standard immunosuppressive therapy, rather than standard immunosuppressive therapy alone. The choice of antibody therapy depends upon an assessment of the patient's risk of acute rejection  (<a class="graphic graphic_algorithm graphicRef134945" href="/z/d/graphic/134945.html" rel="external">algorithm 1</a>). (See <a class="local">'Assessment of immunologic risk'</a> below.)</p><p>There are select patients to whom we do <strong>not</strong> administer antibody induction therapy:</p><p class="bulletIndent1"><span class="glyph">●</span>Recipients of two-haplotype-identical, living, related donor kidneys. These patients are at very low risk for acute rejection; thus, we do not administer antibody therapy as part of the induction regimen in this group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recipients of a kidney transplant who have another functioning solid organ transplant such as a liver, lung, or heart and are currently being administered immunosuppressive agents [<a href="#rid1">1</a>]. Such patients generally do not get induction therapy, as they have been on long-term maintenance immunosuppression and are therefore at increased infection risk with lymphocyte depletion.</p><p></p><p>However, clinical practice varies worldwide and induction therapy is frequently center specific; at some transplant centers in other countries, induction therapy is not routinely administered.</p><p>Several randomized, controlled trials and meta-analyses have shown that induction therapy consisting of biologic antibodies plus standard immunosuppressive therapy, compared with standard immunosuppressive therapy alone, reduces the risk of kidney allograft rejection and may reduce the risk of short-term graft loss [<a href="#rid2">2-4</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a 2017 Cochrane systematic review that included 17 randomized trials (2044 kidney transplant recipients) comparing rabbit or <a class="drug drug_general" data-topicid="9107" href="/z/d/drug information/9107.html" rel="external">horse antithymocyte globulin</a> (ATG) with placebo or no treatment for induction therapy, ATG reduced the risk of acute rejection (relative risk [RR] 0.63, 95% CI 0.51-0.78) [<a href="#rid4">4</a>]. When used together with calcineurin inhibitor (CNI)-based maintenance immunosuppression, ATG possibly reduced the risk of death (RR 0.75, 95% CI 0.27-2.06 at 1 to 2 years and RR 0.94, 95% CI 0.11-7.81 at 5 years) and graft loss (RR 0.65, 95% CI 0.36-1.19 at 1 to 2 years), but these results were not statistically significant. However, ATG increased the risk of cytomegalovirus (CMV) infection (RR 1.55, 95% 1.24-1.95), leukopenia (RR 3.86, 95% CI 2.79-5.34), and thrombocytopenia (RR 2.41, 95% CI 1.61-3.61).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 2010 Cochrane systematic review that included 32 randomized trials (5854 kidney transplant recipients) comparing an interleukin (IL) 2 receptor antagonist (<a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a> or daclizumab) with placebo for induction therapy, use of an IL-2 receptor antagonist reduced the risk of biopsy-proven acute rejection at one year (14 trials; RR 0.72, 95% CI 0.64-0.81) [<a href="#rid3">3</a>]. Treatment with an IL-2 receptor antagonist also reduced the risk of graft loss at one year (24 trials; RR 0.75, 95% CI 0.62-0.90) but not beyond this.</p><p></p><p>Standard immunosuppressive therapy is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy"</a>.)</p><p class="headingAnchor" id="H2701731707"><span class="h2">Types of antibody therapy</span><span class="headingEndMark"> — </span>Available antibodies for induction therapy include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antilymphocyte antibodies </strong>– Antilymphocyte antibodies include both polyclonal and monoclonal antibodies:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Polyclonal antilymphocyte antibodies contain antibodies to a wide variety of human T cell surface antigens, including the major histocompatibility complex (MHC) antigens. Thymoglobulin is a polyclonal immunosuppressive agent that is generated in rabbits. Although there is no generic formulation, it is commonly referred to as <a class="drug drug_general" data-topicid="10026" href="/z/d/drug information/10026.html" rel="external">rabbit antithymocyte globulin</a>, or rATG. This may produce some confusion, as there are other rATGs, such as one produced by Fresenius. The immunogen for rATG-Thymoglobulin is human thymocytes, while, for rATG-Fresenius, the immunogen is a Jurkat T cell leukemia line. The preparations also differ in potency and efficacy. Another polyclonal antibody, ATGAM, is a purified gamma globulin solution obtained by immunization of horses with human thymocytes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monoclonal antilymphocyte antibodies include <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>. Alemtuzumab is a humanized anti-CD52 panlymphocytic (both B and T cells) monoclonal antibody, the use of which is declining in the United States [<a href="#rid5">5</a>]. Alemtuzumab is not available in many countries in Europe.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IL-2 receptor antagonists</strong> – Full T cell activation leads to the calcineurin-mediated stimulation of the transcription, translation, and secretion of IL-2, an essential autocrine growth factor that induces T cell proliferation. Thus, an attractive therapeutic option is the abrogation of IL-2 activity via the administration of anti-IL-2 receptor antibodies. The only IL-2 receptor antibody that is available is <a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-CD20 antibodies</strong> – <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> is an anti-CD20 monoclonal antibody that depletes CD20-positive B cells. It is approved for treatment of multiple conditions, but it has been used most commonly among transplant recipients for treatment of posttransplant lymphoproliferative disease and for desensitization for human leukocyte antigen (HLA)- and ABO-incompatible transplants and the treatment of antibody-meditated rejection. (See  <a class="medical medical_review" href="/z/d/html/7335.html" rel="external">"Treatment and prevention of post-transplant lymphoproliferative disorders"</a> and  <a class="medical medical_review" href="/z/d/html/7351.html" rel="external">"Kidney transplantation in adults: HLA-incompatible transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/7326.html" rel="external">"Kidney transplantation in adults: Prevention and treatment of antibody-mediated rejection"</a>.)</p><p></p><p class="headingAnchor" id="H75641488"><span class="h1">ASSESSMENT OF IMMUNOLOGIC RISK</span><span class="headingEndMark"> — </span>An important element of some approaches to induction protocols involves the attempt to identify patients at high risk of acute rejection. With this view, more aggressive immunosuppression is justified in patients at significantly increased risk of rejection  (<a class="graphic graphic_figure graphicRef108391" href="/z/d/graphic/108391.html" rel="external">figure 1</a>). Risk factors for acute rejection include the following [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>One or more human leukocyte antigen (HLA) mismatches</p><p class="bulletIndent1"><span class="glyph">●</span>Younger recipient and older donor age</p><p class="bulletIndent1"><span class="glyph">●</span>Calculated panel reactive antibody (cPRA) greater than 20 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of a donor-specific antibody (DSA)</p><p class="bulletIndent1"><span class="glyph">●</span>Blood group incompatibility</p><p class="bulletIndent1"><span class="glyph">●</span>Delayed onset of graft function</p><p class="bulletIndent1"><span class="glyph">●</span>Cold ischemia time greater than 24 hours</p><p></p><p>Patients with one or more of the above risk factors are considered to be at <strong>high</strong> immunologic risk for acute rejection. Those who have none of the above risk factors are considered to be at <strong>low</strong> immunologic risk. (See <a class="local">'Patients at high risk of rejection'</a> below and <a class="local">'Patients at low risk of rejection'</a> below.)</p><p class="headingAnchor" id="H400414788"><span class="h1">APPROACH TO INDUCTION THERAPY</span></p><p class="headingAnchor" id="H1801958490"><span class="h2">Patients at high risk of rejection</span><span class="headingEndMark"> — </span>For patients at high immunologic risk of acute rejection (see <a class="local">'Assessment of immunologic risk'</a> above), we recommend induction therapy with rATG-Thymoglobulin rather than an interleukin (IL) 2 receptor antagonist (<a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a>)  (<a class="graphic graphic_algorithm graphicRef134945" href="/z/d/graphic/134945.html" rel="external">algorithm 1</a>). In patients who are unable to tolerate rATG-Thymoglobulin, such as those who are hypotensive, leukopenic, and/or thrombocytopenic at the time of transplant surgery, basiliximab is an alternative option. This approach is consistent with the 2009 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines [<a href="#rid6">6</a>]. Dosing and administration of these agents are discussed below. (See <a class="local">'Dosing and administration'</a> below.)</p><p>In patients at increased risk for acute rejection, rATG-Thymoglobulin is more effective than <a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a> in preventing rejection [<a href="#rid3">3,7-13</a>]. The efficacy and safety of rATG-Thymoglobulin versus basiliximab in high-risk patients was best assessed in a multicenter trial that randomly assigned 278 first deceased-donor kidney transplant recipients to a five-day course of rATG-Thymoglobulin or two doses of basiliximab [<a href="#rid7">7</a>]. All patients received <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> for maintenance immunosuppression, as well as antiviral prophylaxis with <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a>.</p><p class="bulletIndent1"><span class="glyph">●</span>At one year, patients receiving rATG-Thymoglobulin had lower rates of acute rejection (16 versus 26 percent) and acute rejection requiring antibody treatment (1.4 versus 8 percent). Patient and graft survival were similar between the groups. Although serious adverse event rates were similar between the groups, patients treated with rATG-Thymoglobulin had a higher rate of infection (86 versus 75 percent) but a lower incidence of cytomegalovirus (CMV) disease (8 versus 18 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At five years, rates of acute rejection and acute rejection requiring antibody treatment remained lower among those treated with rATG-Thymoglobulin compared with <a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a> (16 versus 30 percent and 3 versus 12 percent, respectively) [<a href="#rid10">10</a>]. Patients treated with rATG-Thymoglobulin also had a lower composite endpoint of acute rejection, graft loss, and death at five years (39 versus 52 percent) and incidence of treated CMV infection (7 versus 17 percent); however, the incidence of malignancy did not differ. Thus, the relative benefits of rATG-Thymoglobulin were sustained over a five-year period after surgery.</p><p></p><p>Compared with rATG-Thymoglobulin, <a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a> may be associated with increased occurrence of de novo donor-specific antibodies (DSAs) and antibody-mediated rejection (ABMR). This was suggested by a study of 114 consecutive recipients of deceased-donor kidneys who had DSAs but a negative crossmatch at the time of transplantation [<a href="#rid14">14</a>]. At 36 months, compared with basiliximab, rATG-Thymoglobulin was associated with decreases in de novo DSA and ABMR. (See  <a class="medical medical_review" href="/z/d/html/7326.html" rel="external">"Kidney transplantation in adults: Prevention and treatment of antibody-mediated rejection"</a>.)</p><p class="headingAnchor" id="H3991962923"><span class="h2">Patients at low risk of rejection</span><span class="headingEndMark"> — </span>For patients who are at low immunologic risk of acute rejection (see <a class="local">'Assessment of immunologic risk'</a> above), either an IL-2 receptor antagonist (<a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a>) or rATG-Thymoglobulin is a reasonable induction therapy agent  (<a class="graphic graphic_algorithm graphicRef134945" href="/z/d/graphic/134945.html" rel="external">algorithm 1</a>). Some experts prefer rATG-Thymoglobulin based upon data showing lower rates of biopsy-proven acute rejection at one year with rATG-Thymoglobulin [<a href="#rid15">15</a>]. Other experts prefer basiliximab based upon studies that have shown similar rates of acute rejection, patient and graft survival, and infection with rATG-Thymoglobulin and IL-2 receptor antibodies in low-risk patients. The 2009 KDIGO clinical practice guidelines recommend the use of IL-2 receptor antibodies as first-line induction therapy in patients not at high immunologic risk [<a href="#rid6">6</a>]. Dosing and administration of these agents are discussed below. (See <a class="local">'Dosing and administration'</a> below.)</p><p>Data from randomized trials and retrospective studies have shown that <a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a> and rATG-Thymoglobulin have similar rates of acute rejection, patient and graft survival, and infection in low-risk patients [<a href="#rid9">9,16-19</a>]. The best data come from a multicenter trial from Germany, in which 615 low-risk transplant recipients were randomly assigned to one of three different immunosuppressive regimens: basiliximab induction with long-term maintenance glucocorticoids, basiliximab induction with rapid glucocorticoid withdrawal (within eight days of transplantation), or rATG-Thymoglobulin induction with rapid glucocorticoid withdrawal [<a href="#rid17">17</a>]. All patients received low-dose extended-release <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> capsules and <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil as maintenance immunosuppression. At 12 months, rates of biopsy-proven acute rejection were similar among the rATG-Thymoglobulin and both basiliximab groups (10 versus 11 and 11 percent). In addition, there were no differences in patient or graft survival, graft function, infections, or malignancy. Similar findings were reported in two other smaller randomized trials, one of which also found comparable patient and graft survival between basiliximab and rATG-Thymoglobulin at five years [<a href="#rid16">16,18,19</a>].</p><p class="headingAnchor" id="H3614073788"><span class="h2">Dosing and administration</span></p><p class="headingAnchor" id="H2148164097"><span class="h3">rATG-Thymoglobulin</span><span class="headingEndMark"> — </span>The optimal dosing strategy for rATG-Thymoglobulin is not known, and practice may vary between centers. Our approach is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>At our centers, the targeted cumulative dose for rATG-Thymoglobulin varies depending upon the patient's risk of rejection. For patients at high risk of rejection, we use higher doses of rATG-Thymoglobulin and target a cumulative dose of 5 to 6 mg/kg. For patients at low risk of rejection, we target a cumulative dose of 3 mg/kg. (See <a class="local">'Assessment of immunologic risk'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We administer the initial dose of intravenous (IV) rATG-Thymoglobulin (1 to 2 mg/kg) intraoperatively, in combination with IV <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> (7 mg/kg). rATG-Thymoglobulin should not be given if, at presentation, the patient is hypotensive (systolic blood pressure &lt;90 mmHg), the white blood cell (WBC) count is less than 2000/microL, or the platelet count is less than 75,000/microL. If rATG-Thymoglobulin cannot be given, we administer <a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a>. (See <a class="local">'Basiliximab'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Following the initial intraoperative dose of rATG-Thymoglobulin, we administer 1 to 2 mg/kg of rATG-Thymoglobulin per day for the next one to two days (ie, a total of two to three doses), depending upon the targeted cumulative dose. The dose of rATG-Thymoglobulin is skipped if the WBC count falls to less than 2000/microL or the platelet count decreases to less than 75,000/microL. A half dose of rATG-Thymoglobulin is administered for a WBC between 2000 and 3000/microL or a platelet count between 75,000 and 100,000/microL. If a dose of rATG-Thymoglobulin is skipped due to cytopenia, some experts would withhold any further doses, even if the intended cumulative dose has not been given, with the rationale that the development of cytopenia indicates that the patient has received sufficient rATG-Thymoglobulin. Other experts would resume therapy within 24 hours of skipping a dose and administer the cumulative dose target, given concerns that administering doses lower than the cumulative dose target may increase the risk of rejection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>This rATG-Thymoglobulin regimen is combined with maintenance immunosuppressive therapy, which begins preoperatively. Selection and initiation of a maintenance immunosuppressive regimen are described in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy"</a>.)</p><p></p><p>Support for intraoperative administration of rATG-Thymoglobulin comes from a trial of 58 deceased-donor transplant recipients who were randomly assigned to receive either intraoperative or postoperative rATG-Thymoglobulin therapy, with both groups receiving the same cumulative doses of the agent [<a href="#rid20">20</a>]. Intraoperative administration resulted in a lower incidence of delayed graft function (15 versus 36 percent) and a decreased posttransplantation length of hospital stay.</p><p>rATG-Thymoglobulin induction has been dosed from 1 to 6 mg/kg per dose, and the duration may range from 1 to 10 days; however, a more typical regimen is 1.5 mg/kg for three to five days [<a href="#rid20">20-28</a>].</p><p>The optimal cumulative dose for rATG-Thymoglobulin is unknown but is felt to total 3 to 6 mg/kg [<a href="#rid23">23,26,28</a>]. Total doses of 5.7 mg/kg, which are, on average, given as 1.5 mg/kg per day, have been shown to produce similar outcomes in high-risk recipients who received an average of 10.3 mg/kg [<a href="#rid27">27</a>]. Higher doses and prolonged duration of induction agents are thought to be associated with an increased risk of infection, serum sickness, and the potential development of lymphoma, while low doses that are &lt;3 mg/kg may not effectively prevent acute rejection [<a href="#rid20">20</a>]. Some programs use lower doses for low-risk recipients of living-related-donor kidneys and higher doses for recipients of deceased-donor kidneys and others perceived to be at higher risk for rejection.</p><p class="headingAnchor" id="H2070381070"><span class="h3">Basiliximab</span><span class="headingEndMark"> — </span>Dosing and administration of <a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a> is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>We administer IV <a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a> 20 mg intraoperatively in combination with IV <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> (7 mg/kg), and 20 mg on postoperative day 4.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">Basiliximab</a> is combined with maintenance immunosuppressive therapy, which begins preoperatively. Selection and initiation of a maintenance immunosuppressive regimen are described in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy"</a>.)</p><p></p><p class="headingAnchor" id="H2822530369"><span class="h2">Special populations</span></p><p class="headingAnchor" id="H849138285"><span class="h3">Recipients of an HLA-incompatible kidney transplant</span><span class="headingEndMark"> — </span>The approach to induction therapy in human leukocyte antigen (HLA)-incompatible kidney transplantation differs from that used in most HLA-compatible transplants. This is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7351.html" rel="external">"Kidney transplantation in adults: HLA-incompatible transplantation", section on 'Transplant immunosuppression'</a>.)</p><p class="headingAnchor" id="H1377439869"><span class="h3">Recipients of an ABO-incompatible kidney transplant</span><span class="headingEndMark"> — </span>The optimal induction therapy in patients receiving a kidney transplant from an ABO-incompatible donor is not known. Such recipients of an ABO-incompatible donor kidney are considered to be at high immunologic risk for rejection and should be considered for rATG-Thymoglobulin as part of their induction immunosuppressive therapy. In addition to induction therapy, additional measures such as plasmapheresis and immunoabsorption are generally required to decrease circulating ABO antibody titers and reduce the risk of acute ABMR. ABO-incompatible transplantation is being performed less frequently given the increased emphasis on kidney paired donation. (See <a class="local">'Assessment of immunologic risk'</a> above and <a class="local">'Patients at high risk of rejection'</a> above and  <a class="medical medical_review" href="/z/d/html/115382.html" rel="external">"Kidney transplantation in adults: Kidney paired donation"</a> and  <a class="medical medical_review" href="/z/d/html/113661.html" rel="external">"Kidney transplantation in adults: ABO-incompatible transplantation"</a>.)</p><p class="headingAnchor" id="H4084845302"><span class="h3">Recipients with HIV</span><span class="headingEndMark"> — </span>Transplant recipients with HIV, compared with those without HIV, have a higher risk of acute rejection and, therefore, would theoretically benefit from antibody induction therapy [<a href="#rid29">29</a>]. However, given the underlying immunosuppressed state of patients with HIV, prolonged lymphocyte depletion with antibody induction therapy could potentially increase their risk of developing opportunistic infections.</p><p>The use of induction immunosuppression in kidney transplant recipients with HIV remains controversial, and there is no uniform agreement among UpToDate authors and editors about the optimal approach in these patients. Some centers avoid the use of antibody induction therapy among transplant recipients with HIV. In centers that use antibody induction therapy, some use <a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a> (an IL-2 receptor antibody) based upon data from two studies of kidney transplant recipients with HIV that demonstrated an increased risk of infection among those treated with rATG-Thymoglobulin [<a href="#rid30">30,31</a>]. Other centers prefer to use rATG-Thymoglobulin given its superior efficacy in preventing acute rejection in recipients without HIV.</p><p>One study of 830 kidney transplant recipients with HIV compared clinical outcomes among patients treated with rATG-Thymoglobulin, an IL-2 receptor antibody, or no induction therapy [<a href="#rid32">32</a>]. Compared with no induction, induction with either rATG-Thymoglobulin or an IL-2 receptor antibody was associated with a decreased risk of delayed graft function (relative risk [RR] 0.66, 95% CI 0.51-0.84) and death-censored graft loss (hazard ratio [HR] 0.47, 95% CI 0.24-0.89). Antibody therapy did not significantly reduce the risk of biopsy-confirmed acute rejection. Notably, antibody induction therapy was not associated with an increased risk of infection.</p><p class="headingAnchor" id="H2168671344"><span class="h1">INFREQUENTLY USED INDUCTION THERAPIES</span></p><p class="headingAnchor" id="H2626885444"><span class="h2">Alemtuzumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">Alemtuzumab</a> is a humanized anti-CD52 panlymphocytic (both B and T cells) monoclonal antibody that is approved for treatment of chronic lymphocytic leukemia. Alemtuzumab induction therapy is used in approximately 10 percent of kidney transplant recipients in the United States.</p><p>We do not routinely use <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a> as induction therapy in most patients undergoing kidney transplantation. Although randomized trials comparing alemtuzumab with either rATG-Thymoglobulin or <a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a> have shown similar or lower rates of acute rejection [<a href="#rid33">33-36</a>], there are concerns that its benefits in reducing acute rejection may decrease over time [<a href="#rid33">33</a>]. Other long-term outcomes, including graft and patient survival and development of chronic allograft nephropathy, may also be worse in patients receiving alemtuzumab compared with rATG-Thymoglobulin and interleukin (IL) 2 receptor antagonists [<a href="#rid34">34,37</a>]. In addition, alemtuzumab is not readily available to all medical centers that perform kidney transplantation.</p><p>Some centers use <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a> as induction therapy for recipients of a human leukocyte antigen (HLA)-incompatible kidney transplant following HLA desensitization, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7351.html" rel="external">"Kidney transplantation in adults: HLA-incompatible transplantation", section on 'Transplant immunosuppression'</a>.)</p><p><a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">Alemtuzumab</a> is administered as a single intravenous (IV) dose of 30 mg at the time of transplantation.</p><p class="headingAnchor" id="H2681543173"><span class="h2">Rituximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> is an anti-CD20 monoclonal antibody that depletes CD20-positive B cells. We do <strong>not</strong> routinely use rituximab as induction therapy in most patients undergoing kidney transplantation, as rituximab does not appear to add benefit and may cause harm among recipients of HLA- and ABO-compatible allografts.</p><p>Two randomized trials have evaluated <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> as induction therapy in kidney transplant recipients:</p><p class="bulletIndent1"><span class="glyph">●</span>In one trial that randomly assigned 136 kidney transplant recipients to induction therapy with single-dose <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (375 mg/m<sup>2</sup>) or placebo, rates of acute rejection, mortality, and bacterial or viral infection at six months were similar between the groups [<a href="#rid38">38</a>]. However, three-year mortality was higher among rituximab-treated patients (12 versus 0 percent); deaths were related to fungal pneumonia (n = 1), pulmonary carcinoma (n = 1), and myocardial infarction and/or cardiac arrest (n = 6) [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second trial that randomly assigned 280 kidney transplant recipients to induction therapy with single-dose <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (375 mg/m<sup>2</sup>) or placebo, overall rates of acute rejection were comparable at six months posttransplantation [<a href="#rid40">40</a>]. However, among high-risk patients (defined as having a panel reactive antibody [PRA] &gt;6 percent or retransplantation), rates of rejection were lower in those receiving rituximab (18 versus 38 percent). Rituximab-treated patients had a higher incidence of neutropenia (24 versus 2 percent), but the risk of infection and malignancy was the same between the groups at two years.</p><p></p><p><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> has been used for desensitization for HLA- and ABO-incompatible transplants, as discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/113661.html" rel="external">"Kidney transplantation in adults: ABO-incompatible transplantation", section on 'Approach to ABOI transplantation'</a> and  <a class="medical medical_review" href="/z/d/html/7351.html" rel="external">"Kidney transplantation in adults: HLA-incompatible transplantation", section on 'Pretransplant HLA desensitization'</a>.)</p><p class="headingAnchor" id="H2025438601"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110754.html" rel="external">"Society guideline links: Kidney transplantation"</a>.)</p><p class="headingAnchor" id="H849988127"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Induction therapy is immunosuppressive therapy administered at the time of kidney transplantation to reduce the risk of allograft rejection. In general, induction strategies fall into one of two categories. The first relies upon high doses of conventional immunosuppressive agents, while the more commonly used strategy utilizes either T cell-depleting or interleukin (IL) 2 receptor-blocking antibodies in combination with lower doses of conventional agents. (See <a class="local">'Introduction'</a> above and <a class="local">'Types of antibody therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for induction therapy</strong> – For <strong>most</strong> patients undergoing kidney transplantation, we suggest induction therapy consisting of antibody therapy plus standard immunosuppressive therapy, rather than standard immunosuppressive therapy alone (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>)  (<a class="graphic graphic_algorithm graphicRef134945" href="/z/d/graphic/134945.html" rel="external">algorithm 1</a>). Select patients to whom we do <strong>not</strong> administer antibody induction therapy include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recipients of two-haplotype-identical, living, related allografts, given the decreased immunologic risk of acute rejection</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recipients of a kidney transplant who have another functioning solid organ transplant (eg, liver, lung, or heart) and who are currently being administered immunosuppressive agents, as they have been on long-term maintenance immunosuppression and are therefore at increased infection risk with lymphocyte depletion</p><p></p><p class="bulletIndent1">However, clinical practice varies worldwide and induction therapy is frequently center specific; at some transplant centers in other countries, induction therapy is not routinely administered. (See <a class="local">'Indications for induction therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients at high risk of rejection</strong> – For patients at high immunologic risk of acute rejection, we recommend induction therapy with rATG-Thymoglobulin rather than an IL-2 receptor antagonist (<a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a>) (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). In patients who are unable to tolerate rATG-Thymoglobulin, such as those who are hypotensive, leukopenic, and/or thrombocytopenic at the time of transplant surgery, basiliximab is an alternative option. (See <a class="local">'Patients at high risk of rejection'</a> above and <a class="local">'Dosing and administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients at low risk of rejection</strong> – For patients who are at low immunologic risk of acute rejection, either an IL-2 receptor antagonist (<a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a>) or rATG-Thymoglobulin is a reasonable induction therapy agent. Some experts prefer rATG-Thymoglobulin based upon data showing lower rates of biopsy-proven acute rejection at one year with rATG-Thymoglobulin. Other experts prefer basiliximab based upon studies that have shown similar rates of acute rejection, patient and graft survival, and infection with rATG-Thymoglobulin and IL-2 receptor antibodies in low-risk patients. (See <a class="local">'Patients at low risk of rejection'</a> above and <a class="local">'Dosing and administration'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cassuto JR, Levine MH, Reese PP, et al. The influence of induction therapy for kidney transplantation after a non-renal transplant. Clin J Am Soc Nephrol 2012; 7:158.</a></li><li><a class="nounderline abstract_t">Szczech LA, Berlin JA, Feldman HI. The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group. Ann Intern Med 1998; 128:817.</a></li><li><a class="nounderline abstract_t">Webster AC, Ruster LP, McGee R, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2010; :CD003897.</a></li><li><a class="nounderline abstract_t">Hill P, Cross NB, Barnett AN, et al. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. Cochrane Database Syst Rev 2017; 1:CD004759.</a></li><li><a class="nounderline abstract_t">Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2016 Annual Data Report: Kidney. Am J Transplant 2018; 18 Suppl 1:18.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 Suppl 3:S1.</a></li><li><a class="nounderline abstract_t">Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355:1967.</a></li><li><a class="nounderline abstract_t">Miller JT, Collins CD, Stuckey LJ, et al. Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression. Pharmacotherapy 2009; 29:1166.</a></li><li><a class="nounderline abstract_t">Tanriover B, Jaikaransingh V, MacConmara MP, et al. Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate. Clin J Am Soc Nephrol 2016; 11:1650.</a></li><li><a class="nounderline abstract_t">Brennan DC, Schnitzler MA. Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med 2008; 359:1736.</a></li><li><a class="nounderline abstract_t">Knight RJ, Kerman RH, Schoenberg L, et al. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function. Transplantation 2004; 78:904.</a></li><li><a class="nounderline abstract_t">Willoughby LM, Schnitzler MA, Brennan DC, et al. Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: application of statistical approaches to reduce bias in observational comparisons. Transplantation 2009; 87:1520.</a></li><li><a class="nounderline abstract_t">Kim JM, Jang HR, Kwon CH, et al. Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study. Transplant Proc 2012; 44:167.</a></li><li><a class="nounderline abstract_t">Brokhof MM, Sollinger HW, Hager DR, et al. Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients. Transplantation 2014; 97:612.</a></li><li><a class="nounderline abstract_t">Hardinger KL, Brennan DC, Schnitzler MA. Rabbit antithymocyte globulin is more beneficial in standard kidney than in extended donor recipients. Transplantation 2009; 87:1372.</a></li><li><a class="nounderline abstract_t">Mourad G, Rostaing L, Legendre C, et al. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004; 78:584.</a></li><li><a class="nounderline abstract_t">Thomusch O, Wiesener M, Opgenoorth M, et al. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial. Lancet 2016; 388:3006.</a></li><li><a class="nounderline abstract_t">Lebranchu Y, Bridoux F, Büchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2:48.</a></li><li><a class="nounderline abstract_t">Al Najjar A, Etienne I, Le Pogamp P, et al. Long-term results of monoclonal anti-Il2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation. Transplant Proc 2006; 38:2298.</a></li><li><a class="nounderline abstract_t">Goggins WC, Pascual MA, Powelson JA, et al. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003; 76:798.</a></li><li><a class="nounderline abstract_t">Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361:1502.</a></li><li><a class="nounderline abstract_t">Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67:1011.</a></li><li><a class="nounderline abstract_t">Agha IA, Rueda J, Alvarez A, et al. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation 2002; 73:473.</a></li><li><a class="nounderline abstract_t">Peddi VR, Bryant M, Roy-Chaudhury P, et al. Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation 2002; 73:1514.</a></li><li><a class="nounderline abstract_t">Stratta RJ, Sundberg AK, Farney AC, et al. Experience with alternate-day thymoglobulin induction in pancreas transplantation with portal-enteric drainage. Transplant Proc 2005; 37:3546.</a></li><li><a class="nounderline abstract_t">Wong W, Agrawal N, Pascual M, et al. Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation. Transpl Int 2006; 19:629.</a></li><li><a class="nounderline abstract_t">Gurk-Turner C, Airee R, Philosophe B, et al. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. Transplantation 2008; 85:1425.</a></li><li><a class="nounderline abstract_t">Stevens RB, Mercer DF, Grant WJ, et al. Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. Transplantation 2008; 85:1391.</a></li><li><a class="nounderline abstract_t">Locke JE, James NT, Mannon RB, et al. Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients. Transplantation 2014; 97:446.</a></li><li><a class="nounderline abstract_t">Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010; 363:2004.</a></li><li><a class="nounderline abstract_t">Carter JT, Melcher ML, Carlson LL, et al. Thymoglobulin-associated Cd4+ T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant 2006; 6:753.</a></li><li><a class="nounderline abstract_t">Kucirka LM, Durand CM, Bae S, et al. Induction Immunosuppression and Clinical Outcomes in Kidney Transplant Recipients Infected With Human Immunodeficiency Virus. Am J Transplant 2016; 16:2368.</a></li><li><a class="nounderline abstract_t">Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364:1909.</a></li><li><a class="nounderline abstract_t">Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008; 22:200.</a></li><li><a class="nounderline abstract_t">3C Study Collaborative Group, Haynes R, Harden P, et al. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. Lancet 2014; 384:1684.</a></li><li><a class="nounderline abstract_t">Farney AC, Doares W, Rogers J, et al. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation 2009; 88:810.</a></li><li><a class="nounderline abstract_t">Sureshkumar KK, Thai NL, Hussain SM, et al. Influence of induction modality on the outcome of deceased donor kidney transplant recipients discharged on steroid-free maintenance immunosuppression. Transplantation 2012; 93:799.</a></li><li><a class="nounderline abstract_t">Tydén G, Genberg H, Tollemar J, et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009; 87:1325.</a></li><li><a class="nounderline abstract_t">Tydén G, Ekberg H, Tufveson G, Mjörnstedt L. A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: a 3-year follow-up. Transplantation 2012; 94:e21.</a></li><li><a class="nounderline abstract_t">van den Hoogen MW, Kamburova EG, Baas MC, et al. Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Transplant 2015; 15:407.</a></li></ol></div><div id="topicVersionRevision">Topic 7353 Version 44.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22076872" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The influence of induction therapy for kidney transplantation after a non-renal transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9599193" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20091551" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Interleukin 2 receptor antagonists for kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28073178" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29292608" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : OPTN/SRTR 2016 Annual Data Report: Kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19845597" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : KDIGO clinical practice guideline for the care of kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17093248" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Rabbit antithymocyte globulin versus basiliximab in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19792990" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27364616" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18923181" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Long-term results of rabbit antithymocyte globulin and basiliximab induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15385812" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19461489" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: application of statistical approaches to reduce bias in observational comparisons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22310606" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24531846" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19424038" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Rabbit antithymocyte globulin is more beneficial in standard kidney than in extended donor recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15446319" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27871759" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12095056" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16980070" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-term results of monoclonal anti-Il2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14501856" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12737859" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Tolerogenic immunosuppression for organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10221486" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11884948" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Short course induction immunosuppression with thymoglobulin for renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12023634" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16298656" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Experience with alternate-day thymoglobulin induction in pancreas transplantation with portal-enteric drainage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16827679" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18497682" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18497677" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24162248" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21083386" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Outcomes of kidney transplantation in HIV-infected recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16539632" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Thymoglobulin-associated Cd4+ T-cell depletion and infection risk in HIV-infected renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27111897" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Induction Immunosuppression and Clinical Outcomes in Kidney Transplant Recipients Infected With Human Immunodeficiency Virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21591943" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Alemtuzumab induction in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18339140" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25078310" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19920781" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22290269" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Influence of induction modality on the outcome of deceased donor kidney transplant recipients discharged on steroid-free maintenance immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19424032" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22872297" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: a 3-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25612493" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
